Trader Evotec AG - EVT CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.085 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.017913% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | -0.004309% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | EUR | ||||||||
| Marge | 20% | ||||||||
| Bourse | Germany | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Evotec SE ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | 18.055 |
| Ouvert* | 17.98 |
| Variation sur 1 an* | -35.73% |
| Fourchette du jour* | 17.575 - 17.98 |
| Fourchette sur 52 semaines | 14.80-29.71 |
| Volume moyen (10 jours) | 521.93K |
| Volume moyen (3 mois) | 8.76M |
| Capitalisation boursière | 3.21B |
| Ratio C/B | -100.00K |
| Actions en circulation | 176.94M |
| Revenu | 697.83M |
| EPS | -1.02 |
| Dividende (rendement en %) | N/A |
| Bêta | 0.82 |
| Prochaine date de publication des résultats | Mar 28, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| Mar 21, 2023 | 18.055 | 0.085 | 0.47% | 17.970 | 18.315 | 17.910 |
| Mar 20, 2023 | 17.850 | -0.110 | -0.61% | 17.960 | 18.065 | 17.540 |
| Mar 17, 2023 | 18.075 | -0.325 | -1.77% | 18.400 | 18.690 | 17.835 |
| Mar 16, 2023 | 18.265 | 0.700 | 3.99% | 17.565 | 18.295 | 17.375 |
| Mar 15, 2023 | 17.125 | -0.495 | -2.81% | 17.620 | 17.670 | 16.780 |
| Mar 14, 2023 | 17.640 | 0.375 | 2.17% | 17.265 | 17.890 | 17.265 |
| Mar 13, 2023 | 17.280 | 0.125 | 0.73% | 17.155 | 17.400 | 16.825 |
| Mar 10, 2023 | 17.130 | 0.390 | 2.33% | 16.740 | 17.330 | 16.675 |
| Mar 9, 2023 | 17.255 | -0.185 | -1.06% | 17.440 | 17.445 | 17.110 |
| Mar 8, 2023 | 17.535 | -0.085 | -0.48% | 17.620 | 17.800 | 17.315 |
| Mar 7, 2023 | 17.745 | -0.175 | -0.98% | 17.920 | 18.220 | 17.575 |
| Mar 6, 2023 | 17.540 | 0.085 | 0.49% | 17.455 | 17.575 | 17.150 |
| Mar 3, 2023 | 17.190 | 0.300 | 1.78% | 16.890 | 17.220 | 16.760 |
| Mar 2, 2023 | 16.615 | 0.205 | 1.25% | 16.410 | 16.770 | 16.410 |
| Mar 1, 2023 | 16.590 | -0.515 | -3.01% | 17.105 | 17.130 | 16.525 |
| Feb 28, 2023 | 16.975 | -0.650 | -3.69% | 17.625 | 17.625 | 16.905 |
| Feb 27, 2023 | 17.820 | 0.115 | 0.65% | 17.705 | 17.895 | 17.620 |
| Feb 24, 2023 | 17.420 | -0.790 | -4.34% | 18.210 | 18.310 | 17.420 |
| Feb 23, 2023 | 18.310 | -0.115 | -0.62% | 18.425 | 18.550 | 18.235 |
| Feb 22, 2023 | 18.285 | -0.005 | -0.03% | 18.290 | 18.315 | 17.950 |
Evotec AG Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| No events scheduled | ||
- Annuel
- Trimestriel
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Revenu total | 618.034 | 500.924 | 446.437 | 375.405 | 263.765 |
| Revenu | 618.034 | 500.924 | 446.437 | 375.405 | 263.765 |
| Coût des recettes, total | 466.491 | 375.181 | 313.546 | 263.389 | 181.965 |
| Résultat brut | 151.543 | 125.743 | 132.891 | 112.016 | 81.8 |
| Total des frais d'exploitation | 588.901 | 452.368 | 383.843 | 297.942 | 227.038 |
| Total des frais de vente/Généraux/Admin | 105.445 | 77.205 | 66.546 | 57.012 | 42.383 |
| Recherche et développement | 72.2 | 63.945 | 58.432 | 35.619 | 17.614 |
| Charges (revenus) inhabituelles | 12.546 | 3.244 | 11.919 | -11.036 | 1.18 |
| Other Operating Expenses, Total | -67.781 | -67.207 | -66.6 | -47.042 | -16.104 |
| Produits d'exploitation | 29.133 | 48.556 | 62.594 | 77.463 | 36.727 |
| Produits (charges) d'intérêts, nets Hors exploitation | 208.106 | -22.925 | -6.102 | -5.602 | -10.37 |
| Autres, nets | -0.259 | 0.209 | 0.07 | 0.138 | -0.792 |
| Résultat net avant impôts | 236.98 | 25.84 | 56.562 | 71.999 | 25.565 |
| Résultat net après impôts | 215.51 | 6.278 | 37.228 | 84.056 | 23.218 |
| Intérêts minoritaires | 0 | 0 | 0.844 | 0.116 | 0.258 |
| Résultat net avant éléments extra | 215.51 | 6.278 | 38.072 | 84.172 | 23.476 |
| Résultat net | 215.51 | 6.278 | 38.072 | 84.172 | 23.476 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | 215.51 | 6.278 | 38.072 | 84.172 | 23.476 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | 215.51 | 6.278 | 38.072 | 84.172 | 23.476 |
| Résultat net dilué | 215.51 | 6.278 | 38.072 | 84.172 | 23.476 |
| Moyenne pondérée des actions diluées | 166.406 | 153.752 | 149.726 | 147.482 | 145.01 |
| BPA dilué hors éléments extraordinaires | 1.29509 | 0.04083 | 0.25428 | 0.57073 | 0.16189 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
| BPA dilué normalisé | 1.36365 | 0.05455 | 0.30667 | 0.52209 | 0.16928 |
| Ajustement pour dilution | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Revenu total | 164.672 | 187.071 | 159.661 | 138.217 | 133.085 |
| Revenu | 164.672 | 187.071 | 159.661 | 138.217 | 133.085 |
| Coût des recettes, total | 132.378 | 134.997 | 116.494 | 112.594 | 102.406 |
| Résultat brut | 32.294 | 52.074 | 43.167 | 25.623 | 30.679 |
| Total des frais d'exploitation | 164.209 | 179.5 | 146.414 | 136.68 | 126.307 |
| Total des frais de vente/Généraux/Admin | 31.566 | 34.408 | 24.654 | 25.189 | 21.194 |
| Recherche et développement | 18.113 | 18.728 | 18.038 | 16.974 | 18.46 |
| Other Operating Expenses, Total | -17.848 | -16.005 | -17.263 | -18.76 | -15.753 |
| Produits d'exploitation | 0.463 | 7.571 | 13.247 | 1.537 | 6.778 |
| Produits (charges) d'intérêts, nets Hors exploitation | -69.555 | -25.191 | 127.127 | 58.478 | 47.692 |
| Autres, nets | 0.359 | -0.216 | 0.017 | -0.03 | -0.03 |
| Résultat net avant impôts | -68.733 | -17.836 | 140.391 | 59.985 | 54.44 |
| Résultat net après impôts | -73.242 | -31.478 | 134.271 | 60.015 | 52.702 |
| Résultat net avant éléments extra | -73.242 | -31.478 | 134.271 | 60.015 | 52.702 |
| Résultat net | -73.242 | -31.478 | 134.271 | 60.015 | 52.702 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -73.242 | -31.478 | 134.271 | 60.015 | 52.702 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -73.242 | -31.478 | 134.271 | 60.015 | 52.702 |
| Résultat net dilué | -73.242 | -31.478 | 134.271 | 60.015 | 52.702 |
| Moyenne pondérée des actions diluées | 176.703 | 172.677 | 164.525 | 164.33 | 164.088 |
| BPA dilué hors éléments extraordinaires | -0.41449 | -0.18229 | 0.81611 | 0.36521 | 0.32118 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
| BPA dilué normalisé | -0.41449 | -0.15454 | 0.84222 | 0.36791 | 0.32118 |
| Charges (revenus) inhabituelles | 7.372 | 4.491 | 0.683 | ||
| Intérêts minoritaires | 0 |
- Annuel
- Trimestriel
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 1100.94 | 658.844 | 469.53 | 249.769 | 177.783 |
| Espèces et placements à court terme | 858.498 | 492.634 | 321.662 | 149.879 | 91.947 |
| Trésorerie et équivalents | 699.326 | 422.58 | 277.034 | 109.055 | 67.017 |
| Investissements à court terme | 159.172 | 70.054 | 44.628 | 40.824 | 24.93 |
| Total des créances, nettes | 176.754 | 122.221 | 117.844 | 74.772 | 63.624 |
| Accounts Receivable - Trade, Net | 150.692 | 91.612 | 93.702 | 58.851 | 56.198 |
| Total Inventory | 25.793 | 13.585 | 10.749 | 5.66 | 5.568 |
| Prepaid Expenses | 19.21 | 9.258 | 9.166 | 8.451 | 8.6 |
| Other Current Assets, Total | 20.685 | 21.146 | 10.109 | 11.007 | 8.044 |
| Total Assets | 2235.16 | 1462.34 | 1180.91 | 771.883 | 666.475 |
| Property/Plant/Equipment, Total - Net | 484.597 | 337.297 | 239.229 | 90.519 | 76.069 |
| Property/Plant/Equipment, Total - Gross | 686.086 | 481.879 | 350.415 | 164.143 | 131.682 |
| Accumulated Depreciation, Total | -201.489 | -144.582 | -111.186 | -73.624 | -55.613 |
| Goodwill, Net | 257.569 | 247.37 | 255.919 | 220.791 | 220.447 |
| Intangibles, Net | 30.851 | 98.036 | 116.994 | 122.989 | 135.033 |
| Long Term Investments | 287.009 | 59.021 | 41.252 | 28.99 | 22.141 |
| Note Receivable - Long Term | 55.966 | 36.485 | 22.718 | 14.601 | 11.168 |
| Other Long Term Assets, Total | 18.229 | 25.284 | 35.27 | 44.224 | 23.834 |
| Total Current Liabilities | 324.516 | 208.459 | 178.955 | 196.275 | 242.945 |
| Accounts Payable | 72.598 | 42.549 | 31.319 | 31.137 | 26.078 |
| Accrued Expenses | 33.983 | 34.728 | 29.174 | 25.67 | 18.351 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 50.609 | 30.008 | 20.731 | 56.919 | 168.468 |
| Other Current Liabilities, Total | 167.326 | 101.174 | 97.731 | 82.549 | 30.048 |
| Total Liabilities | 857.476 | 737.881 | 703.883 | 347.879 | 335.552 |
| Total Long Term Debt | 462.308 | 461.957 | 442.368 | 57.546 | 21.46 |
| Long Term Debt | 326.344 | 331.019 | 324.886 | 54.68 | 20.295 |
| Capital Lease Obligations | 135.964 | 130.938 | 117.482 | 2.866 | 1.165 |
| Deferred Income Tax | 17.688 | 20.399 | 21.199 | 21.517 | 23.692 |
| Minority Interest | 0 | 0 | 0 | 0.876 | 0.992 |
| Other Liabilities, Total | 52.964 | 47.066 | 61.361 | 71.665 | 46.463 |
| Total Equity | 1377.69 | 724.456 | 477.029 | 424.004 | 330.923 |
| Common Stock | 176.608 | 163.915 | 150.903 | 149.063 | 147.533 |
| Additional Paid-In Capital | 1430.14 | 1030.7 | 786.865 | 783.154 | 778.858 |
| Retained Earnings (Accumulated Deficit) | -216.421 | -432.639 | -441.177 | -481.013 | -566.565 |
| Unrealized Gain (Loss) | 3.053 | 4.26 | 4.565 | 6.002 | 6.384 |
| Other Equity, Total | -15.691 | -41.782 | -24.127 | -33.202 | -35.287 |
| Total Liabilities & Shareholders’ Equity | 2235.16 | 1462.34 | 1180.91 | 771.883 | 666.475 |
| Total Common Shares Outstanding | 176.358 | 163.665 | 150.653 | 148.813 | 147.283 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 1061.51 | 1100.94 | 628.306 | 634.802 | 680.401 |
| Espèces et placements à court terme | 855.045 | 858.498 | 427.228 | 459.703 | 470.576 |
| Trésorerie et équivalents | 660.488 | 699.326 | 333.404 | 382.311 | 401.597 |
| Investissements à court terme | 194.557 | 159.172 | 93.824 | 77.392 | 68.979 |
| Total des créances, nettes | 134.019 | 176.754 | 136.615 | 116.179 | 154.67 |
| Accounts Receivable - Trade, Net | 112.617 | 150.692 | 111.501 | 94.166 | 136.494 |
| Total Inventory | 26.076 | 25.793 | 22.519 | 17.254 | 15.237 |
| Prepaid Expenses | 46.373 | 39.895 | 41.944 | 41.666 | 39.918 |
| Total Assets | 2185.02 | 2235.16 | 1767.85 | 1621.12 | 1580.71 |
| Property/Plant/Equipment, Total - Net | 521.357 | 484.597 | 472.825 | 449.474 | 374.93 |
| Goodwill, Net | 257.649 | 257.569 | 253.709 | 252.961 | 254.041 |
| Intangibles, Net | 29.157 | 30.851 | 33.227 | 35.814 | 95.693 |
| Long Term Investments | 236.624 | 287.009 | 303.841 | 175.425 | 108.274 |
| Note Receivable - Long Term | 61.595 | 55.966 | 50.376 | 45.371 | 40.836 |
| Other Long Term Assets, Total | 17.128 | 18.229 | 25.565 | 27.269 | 26.532 |
| Total Current Liabilities | 339.62 | 324.516 | 253.778 | 246.947 | 239.606 |
| Accounts Payable | 74.739 | 72.598 | 56.72 | 51.363 | 54.88 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 50.641 | 50.609 | 49.356 | 63.909 | 30.145 |
| Other Current Liabilities, Total | 214.24 | 201.309 | 147.702 | 131.675 | 154.581 |
| Total Liabilities | 875.162 | 857.476 | 775.17 | 768.542 | 787.661 |
| Total Long Term Debt | 467.926 | 462.308 | 451.255 | 448.949 | 486.933 |
| Long Term Debt | 326.116 | 326.344 | 317.922 | 318.151 | 353.201 |
| Capital Lease Obligations | 141.81 | 135.964 | 133.333 | 130.798 | 133.732 |
| Deferred Income Tax | 17.552 | 17.688 | 19.208 | 19.58 | 20.654 |
| Other Liabilities, Total | 50.064 | 52.964 | 50.929 | 53.066 | 40.468 |
| Total Equity | 1309.86 | 1377.69 | 992.679 | 852.574 | 793.046 |
| Common Stock | 176.953 | 176.608 | 165.111 | 164.608 | 164.561 |
| Additional Paid-In Capital | 1432.45 | 1430.14 | 1035.44 | 1033.67 | 1032.13 |
| Retained Earnings (Accumulated Deficit) | -289.629 | -216.421 | -186.245 | -320.691 | -381.249 |
| Other Equity, Total | -9.912 | -15.691 | -21.625 | -29.333 | -22.395 |
| Total Liabilities & Shareholders’ Equity | 2185.02 | 2235.16 | 1767.85 | 1621.12 | 1580.71 |
| Total Common Shares Outstanding | 176.703 | 176.358 | 164.861 | 164.358 | 164.311 |
| Unrealized Gain (Loss) | 3.053 | 4.32 | |||
| Minority Interest | 0 |
- Annuel
- Trimestriel
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | 215.51 | 6.252 | 37.228 | 84.056 | 23.218 |
| Liquidités provenant des activités d'exploitation | 122.237 | 44.721 | 42.216 | 156.24 | 10.828 |
| Liquidités provenant des activités d'exploitation | 55.596 | 42.122 | 36.456 | 19.288 | 13.725 |
| Amortization | 12.012 | 13.936 | 12.349 | 12.005 | 7.041 |
| Deferred Taxes | 5.066 | 7.49 | 6.706 | -26.117 | -6.131 |
| Éléments non monétaires | -165.371 | 23.865 | 24.342 | 0.364 | 7.904 |
| Cash Taxes Paid | -6.028 | 9.796 | 2.417 | 3.596 | 0.103 |
| Intérêts payés en espèces | 5.429 | 3.465 | 4.49 | 2.279 | 0.822 |
| Variation du fonds de roulement | -0.576 | -48.944 | -74.865 | 66.644 | -34.929 |
| Flux de trésorerie liés aux activités d'investissement | -243.855 | -155.089 | -86.634 | -39.13 | -269.033 |
| Dépenses d'investissement | -118.943 | -99.072 | -31.905 | -27.867 | -17.587 |
| Autres éléments de flux de trésorerie d'investissement, total | -124.912 | -56.017 | -54.729 | -11.263 | -251.446 |
| Flux de trésorerie provenant des activités de financement | 398.43 | 246.409 | 211.263 | -77.764 | 240.724 |
| Éléments de flux de trésorerie de financement | |||||
| Émission (remboursement) d'actions, nette | 404.322 | 251.564 | 1.901 | 1.578 | 92.356 |
| Émission (remboursement) de la dette, nette | -5.892 | -5.155 | 209.362 | -79.342 | 148.368 |
| Effets de change | -0.066 | 9.505 | 1.134 | 2.692 | 0.558 |
| Variation nette de la trésorerie | 276.746 | 145.546 | 167.979 | 42.038 | -16.923 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -73.242 | 215.51 | 246.988 | 112.717 | 52.702 |
| Cash From Operating Activities | 63.618 | 122.237 | 61.902 | 41.105 | 2.459 |
| Changes in Working Capital | 136.86 | -93.273 | -185.086 | -71.612 | -50.243 |
| Cash From Investing Activities | -95.732 | -243.855 | -146.74 | -96.457 | -46.504 |
| Capital Expenditures | -42.921 | -118.943 | -100.183 | -72.573 | -36.297 |
| Other Investing Cash Flow Items, Total | -52.811 | -124.912 | -46.557 | -23.884 | -10.207 |
| Cash From Financing Activities | -5.279 | 398.43 | -7.148 | 12.457 | 17.931 |
| Issuance (Retirement) of Stock, Net | 0.345 | 404.322 | 1.196 | 0.693 | 0.646 |
| Issuance (Retirement) of Debt, Net | -5.624 | -5.892 | -8.344 | 11.764 | 17.285 |
| Foreign Exchange Effects | -1.445 | -0.066 | 2.81 | 2.626 | 5.131 |
| Net Change in Cash | -38.838 | 276.746 | -89.176 | -40.269 | -20.983 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 10.0958 | 17888267 | 197835 | 2022-11-10 | MED |
| Novo Holdings A/S | Venture Capital | 9.8455 | 17444807 | -206374 | 2022-12-31 | LOW |
| Mubadala Investment Company PJSC | Sovereign Wealth Fund | 6.4799 | 11481502 | 2298850 | 2021-11-08 | LOW |
| Government of Abu Dhabi | Government Agency | 6.4788 | 11479533 | 1602555 | 2021-12-31 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 5.0138 | 8883666 | -1796 | 2023-01-31 | LOW |
| BlackRock Asset Management Deutschland AG | Investment Advisor | 3.671 | 6504551 | -2755 | 2022-06-03 | LOW |
| Allianz Global Investors GmbH | Investment Advisor | 2.9667 | 5256528 | -2846371 | 2022-01-07 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.5091 | 4445816 | 7452 | 2023-02-28 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2224 | 3937850 | 851779 | 2022-12-31 | LOW |
| Liontrust Investment Partners LLP | Investment Advisor | 2.1651 | 3836320 | -8983 | 2023-01-31 | LOW |
| Brown Capital Management, LLC | Investment Advisor | 2.165 | 3836114 | -24213 | 2022-09-30 | LOW |
| Oetker (Roland) | Individual Investor | 1.639 | 2904146 | -5440854 | 2022-10-04 | LOW |
| Franklin Equity Group | Investment Advisor | 1.4392 | 2550000 | 0 | 2023-02-28 | LOW |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 1.2419 | 2200506 | 7813 | 2023-02-28 | LOW |
| California State Teachers Retirement System | Pension Fund | 1.0986 | 1946619 | 1704482 | 2022-06-30 | LOW |
| Polar Capital LLP | Investment Advisor/Hedge Fund | 1.0123 | 1793563 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9995 | 1770896 | 17426 | 2023-02-28 | LOW |
| Baillie Gifford & Co. | Investment Advisor | 0.8472 | 1501060 | -9797 | 2023-01-31 | LOW |
| Lanthaler (Werner) | Individual Investor | 0.8196 | 1452188 | 340452 | 2021-09-30 | LOW |
| Evotec SE Management | Corporation | 0.7974 | 1412866 | -233297 | 2021-12-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group500K+
Tradeurs
92K+
Clients actifs par mois
$53M+
Volume d'investissement par mois
$30M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Evotec Company profile
À propos de Evotec SE
Evotec SE est une société basée en Allemagne qui développe des partenariats dans le domaine de la découverte de médicaments. La Société se concentre principalement sur les approches de produits avec un certain nombre de sociétés pharmaceutiques et de biotechnologies, des universitaires, des groupes chargés de la défense des patients et des sociétés de capital-risque. Les solutions de découverte de médicaments se présentent sous la forme de contrats de services, d'alliances intégrées de découverte de médicaments, de partenariats de développement, de licences de candidats médicaments et des des ententes de consultation. Evotec SE intervient dans plusieurs domaines, notamment les neurosciences, le diabète et les complications associées au diabète, la douleur et à l'inflammation, l'oncologie, les maladies infectieuses, ainsi que les maladies respiratoires et à la fibrose. Son pipeline couvre une gamme de domaines thérapeutiques, tels que l’insomnie du SNC, la toux chronique, l’immunologie et l’inflammation, l’endométriose pour la santé de la femme, la néphrologie, les maladies dermatologiques, la maladie fibreuse et les antiviraux, entre autres.
- IndustrieBiotechnology / Medical Research
- AdresseEssener Bogen 7, HAMBURG, Germany (DEU)
- Employés4081
- CEOWolfgang Plischke
| Industry: | Biotechnology & Medical Research (NEC) |
Essener Bogen 7
HAMBURG
HAMBURG 22419
DE
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 500 000 traders du monde entier qui ont choisi de trader avec Capital.com